• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by InnoCare Pharma

    InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Releases 2024 Interim Results and Business Highlights
    From InnoCare Pharma
    Via Business Wire
    British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
    From InnoCare Pharma
    Via Business Wire
    Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
    From InnoCare Pharma
    Via Business Wire
    InnoCare Releases 2023 Results and Business Highlights
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
    From InnoCare Pharma
    Via Business Wire
    InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From InnoCare Pharma
    Via Business Wire
    InnoCare Appoints Xin Fu as Chief Financial Officer
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
    From InnoCare Pharma
    Via Business Wire
    Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
    From InnoCare Pharma
    Via Business Wire
    10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
    From InnoCare Pharma
    Via Business Wire
    InnoCare Releases 2023 Interim Results and Business Highlights
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Approval of Clinical Trial of pan-TRK Inhibitor Zurletrectinib for the Treatment of Pediatric Patients in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China
    From InnoCare Pharma
    Via Business Wire
    Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML)
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces Orelabrutinib Becomes the First and the Only BTK Inhibitor Approved in China for the Treatment of R/R MZL
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Subject Dosed in Clinical Trial of Novel Targeted Protein Degrader ICP-490 in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare Releases 2022 Annual Results and Business Highlights
    From InnoCare Pharma
    Via Business Wire
    InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
    From InnoCare Pharma
    Via Business Wire
    InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
    From InnoCare Pharma
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.